Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.
Mandate

Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.

June 13, 2012

Vinge has advised NeuroNova AB in connection with the merger with Newron Pharmaceuticals S.p.A (”Newron”). NeuroNova AB is a research company within the biotechnology and pharmaceuticals industry which primarily develops therapies for illnesses caused by the death of cells in the central nervous system. Newron is a research company within biotechnology and is listed on the Swiss stock exchange (SIX).

Vinge’s team consisted of, among others, responsible partner Johan Winnerblad and associates Matthias Pannier and Alex Miler.

Related

Vinge advises Mjällby AIF on the transfer of Elliot Stroud to Hull City AFC

 Vinge has advised reigning Allsvenskan champions Mjällby AIF in connection with the transfer of Swedish international Elliot Stroud to Premier League club Hull City AFC.
August 10, 2026

Vinge advises Altor on its public offer for Sleep Cycle

 Snark BidCo, a company controlled by Altor Fund V (No. 1) and Altor Fund V (No. 2) announced a public offer to the shareholders of Sleep Cycle AB to tender all their shares to Snark BidCo. The shares in Sleep Cycle are admitted to trading on Nasdaq Stockholm. After the end of the extended acceptance period, Snark BidCo controls approximately 79.2 percent of the share capital and votes in Sleep Cycle. The total value of the offer was approximately SEK 497 million.
August 07, 2026

Vinge advises SEB Kort in connection with a cross-border merger with AirPlus

Vinge advised SEB Kort in connection with a cross-border merger whereby the subsidiary AirPlus has been absorbed into SEB Kort.
August 06, 2026